New Chemo-Free combo shows promise for colorectal cancer

NCT ID NCT07398326

Recruiting now Disease control Sponsor: Shanghai Changzheng Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase II trial tests a combination of two drugs, anlotinib and sintilimab, as a first treatment for advanced colorectal cancer that has spread but not to the liver. The goal is to shrink tumors and control the disease without using standard chemotherapy. About 37 patients who cannot or prefer not to have chemo will take part at one hospital in China.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anlotinib and sintilimab
What this could lead to: If successful, this could offer a chemotherapy-free treatment option for certain colorectal cancer patients, potentially improving outcomes with fewer side effects.
What could go wrong: This is a small Phase II trial with only 37 participants, so results may not apply broadly. The combination may cause side effects or fail to outperform standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

Second Affiliated Hospital of Naval Medical University
RECRUITING

Shanghai, 200003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.